Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date

    September 2023 in “ Drugs in context ”
    Sofia Faria, Egídio Freitas, Tiago Torres
    Studysummary This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on drugsincontext.com →
    Discuss this study in the Community →

    Research cited in this study 40

    1. Baricitinib for the Treatment of Alopecia Areata Drugs · 2023
    2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    3. The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity Journal of the European Academy of Dermatology and Venereology · 2023
    4. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis Acta dermato-venereologica · 2023
    5. Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2022
    6. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    7. The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies Frontiers in pharmacology · 2022
    8. Baricitinib in Alopecia Areata New England Journal of Medicine · 2022
    9. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    10. Application of Baricitinib in Dermatology Journal of inflammation research · 2022
    11. Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial Journal of the American Academy of Dermatology · 2021
    12. The JAK/STAT Signaling Pathway: From Bench to Clinic Signal Transduction and Targeted Therapy · 2021
    13. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    14. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    15. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    16. Baricitinib: From Rheumatoid Arthritis to COVID-19 Journal of clinical pharmacology · 2021
    17. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    18. Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options Clinical and Experimental Medicine · 2021
    19. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    20. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    21. Treatment of Severe Alopecia Areata with Baricitinib JAAD Case Reports · 2019
    22. Alopecia Areata Patients Show Deficiency of FOXP3+CD39+ T Regulatory Cells and Clonotypic Restriction of Treg TCRβ-Chain, Highlighting the Immunopathological Aspect of the Disease PloS one · 2019
    23. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature Journal of cutaneous medicine and surgery · 2019
    24. JAK Inhibitors and Alopecia Areata Lancet · 2019
    25. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    26. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    27. Nail Changes in Alopecia Areata: An Update and Review International Journal of Dermatology · 2018
    28. Immune Privilege Collapse And Alopecia Development: Is Stress A Factor Skin Appendage Disorders · 2017
    29. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    30. Alopecia Areata: Current Situation and Perspectives Archivos Argentinos De Pediatria · 2017
    31. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    32. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    33. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    34. Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies Autoimmunity reviews · 2016
    35. Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata Journal of Investigative Dermatology · 2015
    36. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    37. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    38. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    39. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    40. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack Journal of Investigative Dermatology · 2007

    Related research 8

    1. Time to Loss of Response for Dupilumab in Ophiasis-Pattern Alopecia Areata JAAD case reports · 2021
    2. Efficacy of Systemic Minoxidil and Tofacitinib Combination in Treatment-Resistant Alopecia Universalis Journal of Cosmetic Dermatology · 2020
    3. A Clinico-Epidemiological Study of Scalp Hair Loss in Children (0–18 Years) in Kota Region, South-East Rajasthan Indian Journal of Dermatology · 2019
    4. Topical and Intralesional Therapies for Alopecia Areata Dermatologic therapy · 2011
    5. Alopecia Areata: Clinical Presentation, Diagnosis, and Unusual Cases Dermatologic Therapy · 2011
    6. Alopecia Areata: Evidence-Based Treatments Seminars in cutaneous medicine and surgery · 2009
    7. Diagnosis of Hair Loss: Clinical Features of Common Causes PubMed · 1992
    8. Diagnosis and Management of the Hair Loss Patient PubMed · 1987